Relacorilant

Drug Overview

Relacorilant is an advanced, selective medication designed to manage the harmful effects of excess cortisol in the body. It is often referred to as a Targeted Therapy or a “Smart Drug” because it focuses on a very specific receptor without affecting others, such as the progesterone receptor. This precision helps reduce the risk of certain side effects common in older medications.

In the medical community, relacorilant is recognized for its role in treating complex hormonal conditions and its potential to make chemotherapy work better in cancer patients. By blocking the “stress hormone” (cortisol) from sending signals to cells, it helps restore balance to the body’s metabolism and immune system. It represents a corporate-standard approach to modern endocrinology and oncology.

• Generic Name: Relacorilant
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Selective Glucocorticoid Receptor Modulator (SGRM)
• Route of Administration: Oral (Capsule/Tablet)
• FDA Approval Status: Investigational (Currently in Phase III clinical trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how relacorilant works, imagine your cells have “docks” called Glucocorticoid Receptors (GR). Cortisol, the body’s stress hormone, is like a ship that parks in these docks to deliver instructions. In certain diseases, there is too much cortisol, and it delivers too many instructions, causing weight gain, high blood sugar, and even helping cancer cells hide from treatment.

Relacorilant acts as a high-tech “barrier” at these docks:

1. Selective Binding: Relacorilant travels through the blood and sits directly in the Glucocorticoid Receptor. Unlike older drugs, it is “selective,” meaning it only blocks the cortisol dock and does not interfere with other important hormones like progesterone.
2. Competitive Inhibition: By sitting in the dock, relacorilant prevents cortisol from attaching. This is called competitive inhibition.
3. Halting Gene Transcription: Once relacorilant is in place, it prevents the receptor from entering the cell’s nucleus. This stops the cell from reading the DNA instructions that usually lead to inflammation, high blood sugar, and tumor survival.
4. Chemotherapy Sensitization: In cancer cells, high cortisol levels can actually prevent chemotherapy from triggering cell death. By blocking cortisol, relacorilant “re-sensitizes” the tumor, making it easier for cancer treatments to destroy the cancer cells.

FDA-Approved Clinical Indications

As of early 2026, relacorilant is being studied in rigorous clinical trials and has not yet received final FDA approval for general sale. Its use is currently limited to research settings.

Oncological Uses (Investigational)

• Ovarian Cancer: Studied in combination with chemotherapy (such as nab-paclitaxel) for recurrent or resistant cases.
• Adrenocortical Carcinoma: Investigated for tumors of the adrenal gland that produce excess cortisol.
• Pancreatic Cancer: Early research into its use alongside standard treatments.

Non-Oncological Uses (Investigational)

• Cushing’s Syndrome: Specifically for patients with endogenous Cushing’s syndrome to manage high blood sugar (hyperglycemia) and high blood pressure.

Dosage and Administration Protocols

Relacorilant is an oral medication taken once daily. The exact dose used in clinical trials depends on the specific condition being treated.

Dose Adjustments:

• Hepatic (Liver) Insufficiency: Patients with moderate liver issues may require a lower starting dose, as the liver processes the medication.
• Renal (Kidney) Insufficiency: No major dose adjustments are typically required for mild to moderate kidney issues, but severe cases require close monitoring.

Clinical Efficacy and Research Results

Clinical data from 2020–2025 highlights the potential of relacorilant to improve patient outcomes significantly.

• Ovarian Cancer (ROSE Study): In Phase II trials, patients receiving relacorilant plus nab-paclitaxel showed a significant improvement in Progression-Free Survival (PFS) compared to those receiving chemotherapy alone. Numerical data suggested an average increase of several months in disease control.
• Cushing’s Syndrome (GRACE Study): Research presented in 2024 and 2025 indicated that patients had a measurable reduction in blood pressure and improved glucose tolerance.
• Safety Comparison: Unlike mifepristone, clinical results show that relacorilant does not cause uterine thickening or low potassium (hypokalemia), which were common problems with older cortisol-blocking drugs.

Safety Profile and Side Effects

Black Box Warning:

None. (Relacorilant is an investigational drug and does not yet have a formal Black Box Warning).

Common Side Effects (>10%)

• Nausea: Mild to moderate stomach upset.
• Fatigue: Feeling unusually tired or weak.
• Abdominal Pain: Discomfort in the stomach area.
• Headache: Persistent but usually manageable head pain.

Serious Adverse Events

• Adrenal Insufficiency: If cortisol is blocked too effectively, the body may not have enough stress response, leading to low blood pressure and extreme weakness.
• Liver Enzyme Elevation: Temporary stress on the liver that requires monitoring.

Management Strategies

• For Nausea: Patients may be advised to take the medication with a small meal or use anti-nausea medicine.
• For Adrenal Insufficiency: Doctors may temporarily stop the drug or provide “stress-dose” steroids if a patient becomes very ill or needs surgery.

Research Areas

Relacorilant is a major focus in Immunotherapy and Regenerative Medicine research. Scientists are investigating how blocking the Glucocorticoid Receptor can “unlock” the immune system. High cortisol levels often suppress the body’s natural “Natural Killer” (NK) cells. Research is currently testing whether relacorilant can help the immune system regenerate its natural ability to find and destroy cancer cells when used alongside Checkpoint Inhibitors.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Baseline Cortisol and ACTH Levels: To establish the starting point of the hormone imbalance.
• Liver Function Tests (LFTs): To ensure the liver is healthy enough to process the drug.
• Pregnancy Test: The drug should not be used during pregnancy.

Precautions During Treatment

• Drug Interactions: Relacorilant can interact with many common drugs (like certain blood thinners or heart medicines). Always provide a full list of medications to your doctor.
• Monitoring Blood Sugar: For patients with diabetes, blood sugar should be checked daily.

“Do’s and Don’ts” List

• Do take your dose at the same time every day to keep hormone levels steady.
• Do report any sudden, extreme dizziness or confusion to your doctor immediately.
• Don’t stop taking the medication suddenly without a doctor’s guidance, as this can cause a “rebound” effect.
• Don’t assume that “natural” cortisol-blocking supplements are safe to take with this medicine.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Relacorilant is an investigational drug and is only available through clinical trials. Always consult with a licensed oncologist or endocrinologist to discuss your specific diagnosis, treatment options, and potential risks. This content reflects data available as of early 2026.